Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer. J Immunother 2018 Jan;41(1):42-44
Date
11/08/2017Pubmed ID
29111983Pubmed Central ID
PMC6339565DOI
10.1097/CJI.0000000000000191Scopus ID
2-s2.0-85038614056 (requires institutional sign-in at Scopus site) 19 CitationsAbstract
In the past decade, the resurgence of immunotherapy has changed the landscape of cancer therapy. Checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen-4, programmed death-1 on lymphocytes, and programmed death ligand-1 on tumors cells are currently utilized in the management of several cancers. These agents are double-edged sword with the positive effect being robust antitumor response but on the other side they can throttle up the normal immunologic homeostasis in a negative way, leading to adverse autoimmune toxicities. These adverse toxicities are frequent if patients have active autoimmune disorders. Here, we report a rare case of quiescent bullous pemphigoid which flared after initiation of pembrolizumab, a programmed death ligand-1 inhibitor.
Author List
Garje R, Chau JJ, Chung J, Wanat K, Zakharia YAuthor
Karolyn A. Wanat MD Chair, Professor in the Dermatology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Acute DiseaseAntibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Disease Progression
Exanthema
Humans
Immunotherapy
Male
Middle Aged
Pemphigus
Prednisone
Programmed Cell Death 1 Receptor
Skin Diseases, Vesiculobullous
Urinary Bladder
Urinary Bladder Neoplasms
Urologic Neoplasms
Withholding Treatment
